Sonova launches Hansaton hearing aids in China



Switzerland-based Sonova Group, a leading provider of innovative hearing care solutions, announced the market launch of Hansaton hearing aids in China as well as a strategic partnership with China’s Sheng Wang Hearing Service Group. Sheng Wang will act as the general agent for the device in mainland China, improving the product accessibility to the hearing-impaired Chinese population. No financial details were disclosed.

Hansaton hearing aids, which integrate German hearing aid technology and high-tech Swiss chips, allow people with hearing loss to have better listening ability and a more natural hearing experience with its intelligent original sound reproduction system. Various styles and customized services are expected to meet the individual needs of different demographic groups.


Reference:

Related news
Sino-US biotech Terns Pharmaceuticals Inc., which operates out of California and Shanghai, has made a filing to hold an initial public offering (IPO) to NASDAQ via the US Securities and Exchange Commission.
China-based Apeloa Pharmaceutical Co., Ltd (000739.HK) announced a partnership agreement with the prestigious Shanghai Jiaotong University (SJTU).
US major Pfizer struck a strategic partnership with compatriot firm Cepheid, a molecular diagnosis specialist.
US-based biopharma Everest Medicines (1952.HK), which has a substantial business presence in China and Asia, announced an amended licensing agreement with US-headquartered Spero Therapeutics Inc., (NASDAQ:SPRO) in relation to Spero’s drug candidate SPR206.
China-based heart valve specialist Venus Medtech (Hangzhou) Inc., (02500.HK) announced first clinical application of its TriGUARD3TM, an innovative anti-embolism distal brain protection device in the Bo’ao Super Hospital.
Recent news
Russian firm Binnopharm Group and India's Glenmark Pharmaceuticals will collaborate on the localized production of the antiviral drug favipiravir in Russia.
A Phase III clinical trial (CT) evaluating Janssen’s HIV vaccine candidate was recently picked up in Argentina after the National Administration of Drugs, Food and Medical Technology (ANMAT) last year temporarily suspended all preventive studies that were not related to COVID-19.
Suzhou-based circulating tumor cells (CTC) specialist Junhui Biotech Co., Ltd struck a strategic partnership with compatriot firm BGI Group (XSHE:300676) subsidiary MGI Tech.
Beijing-based EdiGene Inc., announced an approval nod from the Center for Drug Evaluation (CDE) to initiate a clinical study for ET-01, a CRISPR/Cas 9 gene-editing therapeutic candidate for patients with transfusion dependent β-thalassemia.
Brazil’s Congress last week announced a bill that proposes tax exemptions for drug makers that donate their products to organizations deemed of public interest by the National Health Surveillance Agency (ANVISA).
India’s Bharat Biotech and Brazilian pharmaceutical Precisa Medicamentos last week signed an agreement to supply the former’s SARS-CoV-2 vaccine Covaxin in Brazil, prioritizing the public sector.
BeiGene has a new partner for global development of its programmed death-1 (PD-1) candidate tislelizumab after signing a co-development and commercialization deal with Swiss major Novartis focused on the territories of North America, Japan, EU and six other European countries.
  • 1611036123603
  • China
Analytics Snapshot


Analytics Snapshot